Licensing status

Publication and contact information


Using metrics other than IC50 to assess cancer drug response

An analysis of cellular responses to cancer drugs suggests parameters other than potency should be considered when evaluating their efficacy. A multiparametric analysis of 64 cancer compounds in 53 breast cancer cell lines followed by single-cell analysis found variations in dose-response curves that suggest it could be useful to evaluate compounds using parameters other than IC50 measurements. These parameters include Hill slope (HS) and maximum effect (Emax) values. Next steps include replicating the findings in primary, patient-derived tumor cells and further studying the molecular mechanisms that underlie the observations.

SciBX 6(38); doi:10.1038/scibx.2013.1074
Published online Oct. 3, 2013

Unpatented; licensing status not applicable

Fallahi-Sichani, M. et al. Nat. Chem. Biol.; published online Sept. 8, 2013;
Contact: Peter K. Sorger, Harvard Medical School, Boston, Mass.